The US Pharmacopeial Convention hosts compliance seminar at CPhI China 2015.
The United States Pharmacopeial Convention (USP) hosted a pharmacopeial and regulatory compliance seminar at the 2015 CPhI China conference, held June 24–26, 2015. Keynote speakers included former FDA officials, USP experts, members of the Chinese Pharmacopoeia Commission, and senior pharmaceutical executives.
The seminar was designed to explain the latest quality standards and regulatory updates to the more than 120 participants. Topics included global harmonization with industry standards and regulations, compliance monitoring, and accountability. The USP requirements for elemental impurities, FDA’s metrics program, and the generic-drug market were also discussed.
USP stressed the need for compliance with global regulations and standards due to the increasing expansion of Chinese pharmaceutical companies. “To address growing demands, USP is committed to helping these companies meet pharmacopeial standards, provide training and certification services to help them comply, and also guide them to contribute towards shaping global standards,” said Dr. Feng Bingbing, chairman of the seminar and USP-China general manager, in a press release.
As part of USP’s commitment to the growth of the Chinese pharmaceutical industry, the Convention has built training facilities in the Shanghai Pilot Free Trade Zone. “We will strengthen our collaboration with the Chinese Pharmacopoeia Commission and other partners to share knowledge on pharmacopeial standards, promote industry developments, and improve public health,” said Dr. Feng Bingbing.
Source: USP
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.